Understanding DNA Repair in Myeloid Leukemias to Improve Treatments
Cause and therapeutic impact of DNA-protein crosslink repair defect in myeloid leukemias
This work explores how certain DNA damage is fixed in acute myeloid leukemias to help us find better ways to treat this cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project ID | NIH-11123337 on NIH RePORTER |
What this research studies
Acute myeloid leukemias (AMLs) are serious blood cancers where current treatments, including chemotherapy drugs, don't always work for everyone. Many of these drugs work by creating specific types of DNA damage called DNA-protein crosslinks (DPCs) in cancer cells. This project aims to understand how these DPCs are repaired, especially those caused by common chemotherapy drugs like topotecan. By learning more about these repair processes, we hope to make existing treatments more effective and discover new treatment strategies for AML patients.
Who could benefit from this research
Good fit: This foundational research is relevant for patients with acute myeloid leukemia, particularly those whose cancer cells may have defects in DNA-protein crosslink repair.
Not a fit: Patients with other types of cancer not related to myeloid leukemias or DNA-protein crosslink repair may not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could lead to more effective treatments for acute myeloid leukemia by improving how existing drugs work or by identifying new drug targets.
How similar studies have performed: While the mechanisms of DPC repair are not fully understood, other studies have shown that understanding DNA repair pathways can lead to significant advancements in cancer therapy.
Where this research is happening
Rochester, United States
- Mayo Clinic Rochester — Rochester, United States (Active)
Researchers
- Principal investigator: Kaufmann, Scott H — Mayo Clinic Rochester
- Study coordinator: Kaufmann, Scott H
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.